X
Access Company Profiles

Get business overview, business operations details specific to this market, products and services, latest developments and more...

Business Email

Select Companies

 

Global Pediatric Neuroblastoma Treatment Companies

This report lists the top Global Pediatric Neuroblastoma Treatment companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Global Pediatric Neuroblastoma Treatment industry.

Global Pediatric Neuroblastoma Treatment Top Companies

  1. Baxter International

  2. United Therapeutics Corporation

  3. APEIRON Biologics AG

  4. Y-mAbs Therapeutics, Inc.

  5. CELLECTAR BIOSCIENCES, INC.

*Disclaimer: Top companies sorted in no particular order

 Global Pediatric Neuroblastoma Treatment Market Major Players

Global Pediatric Neuroblastoma Treatment Market Concentration

Global Pediatric Neuroblastoma Treatment Market Concentration

Global Pediatric Neuroblastoma Treatment Company List

                            • United Therapeutics Corporation

                            • APEIRON Biologics AG

                            • Baxter International

                            • Pfizer, Inc.

                            • Bayer AG

                            • MacroGenics, Inc.

                            • Sartorius AG

                            • CELLECTAR BIOSCIENCES, INC.

                            • PROVECTUS BIOPHARMACEUTICALS, INC.

                            • Y-mAbs Therapeutics, Inc.

                            • Amgen

                            • Eli Lilly and Company

                            • F. Hoffmann-La Roche Ltd


                        Specific to Global Pediatric Neuroblastoma Treatment Market
                        Need More Details On Market Players And Competitors?
                        Download Sample

                        Pediatric Neuroblastoma Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)